Open Access

Temozolomide based treatment in glioblastoma: 6 vs. 12 months

  • Authors:
    • Morena Fasano
    • Mario Pirozzi
    • Vincenzo De Falco
    • Chiara Carmen Miceli
    • Stefano Farese
    • Alessia Zotta
    • Vincenzo Famiglietti
    • Pasquale Vitale
    • Ilaria Di Giovanni
    • Christian Brancati
    • Vincenzo Carfora
    • Domenico Solari
    • Teresa Somma
    • Luigi Maria Cavallo
    • Paolo Cappabianca
    • Manuel Conson
    • Roberto Pacelli
    • Fortunato Ciardiello
    • Raffaele Addeo
  • View Affiliations

  • Published online on: July 2, 2024     https://doi.org/10.3892/ol.2024.14551
  • Article Number: 418
  • Copyright: © Fasano et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The Stupp regimen remains the standard treatment for newly diagnosed glioblastomas, although the prognosis remains poor. Several temozolomide alternative schedules have been studied, with extended adjuvant treatment (>6 cycles of temozolomide) frequently used, although different trials have indicated contrasting results. Survival data of 87 patients who received 6 (‘6C’ group) or 12 (‘12C’ group) cycles of temozolomide were collected between 2012 and 2022. A total of 45 patients were included in the 6C group and 42 patients were included in the 12C group. Data on isocitrate dehydrogenase mutation and methylguanine‑DNA‑methyltransferase (MGMT) promoter methylation status were also collected. The 12C group exhibited statistically significantly improved overall survival [OS; 22.8 vs. 17.5 months; hazard ratio (HR), 0.47; 95% CI, 0.30‑0.73; P=0.001] and progression‑free survival (15.3 vs. 9 months; HR, 0.39; 95% CI, 0.25‑0.62; P=0.001). However, in the subgroup analysis according to MGMT status, OS in the 12C group was significantly superior to OS in the 6C group only in the MGMT unmethylated tumors. The present data suggested that extended adjuvant temozolomide appeared to be more effective than the conventional six cycles.
View Figures
View References

Related Articles

Journal Cover

September-2024
Volume 28 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fasano M, Pirozzi M, De Falco V, Miceli CC, Farese S, Zotta A, Famiglietti V, Vitale P, Giovanni I, Brancati C, Brancati C, et al: Temozolomide based treatment in glioblastoma: 6 vs. 12 months. Oncol Lett 28: 418, 2024.
APA
Fasano, M., Pirozzi, M., De Falco, V., Miceli, C.C., Farese, S., Zotta, A. ... Addeo, R. (2024). Temozolomide based treatment in glioblastoma: 6 vs. 12 months. Oncology Letters, 28, 418. https://doi.org/10.3892/ol.2024.14551
MLA
Fasano, M., Pirozzi, M., De Falco, V., Miceli, C. C., Farese, S., Zotta, A., Famiglietti, V., Vitale, P., Giovanni, I., Brancati, C., Carfora, V., Solari, D., Somma, T., Cavallo, L. M., Cappabianca, P., Conson, M., Pacelli, R., Ciardiello, F., Addeo, R."Temozolomide based treatment in glioblastoma: 6 vs. 12 months". Oncology Letters 28.3 (2024): 418.
Chicago
Fasano, M., Pirozzi, M., De Falco, V., Miceli, C. C., Farese, S., Zotta, A., Famiglietti, V., Vitale, P., Giovanni, I., Brancati, C., Carfora, V., Solari, D., Somma, T., Cavallo, L. M., Cappabianca, P., Conson, M., Pacelli, R., Ciardiello, F., Addeo, R."Temozolomide based treatment in glioblastoma: 6 vs. 12 months". Oncology Letters 28, no. 3 (2024): 418. https://doi.org/10.3892/ol.2024.14551